非小细胞肺癌脑转移放化疗联合治疗的临床观察

目的评价Topote Call联合顺铂方案（TPTP方案）治疗非小细胞肺癌脑转移的临床疗效。方法64例非小细胞肺癌伴脑转移的患者随机分两组，全脑放疗后给予TPTP方案或GP方案化疗2-4周期，观察患者对该方案的疗效及毒性反应。结果TPTP方案组脑部病灶客观有效率59．38％，肺部病灶的有效率为62．50％。GP方案组脑部病灶客观有效率53．13％，肺部病灶的有效率为56．25％，‘I哪方案组有效率高于GP组，两组之间差异有统计学意义（P=0．023）。毒性反应TPTP方案组腹泻、脱发发生率高，GP方案组血小板减少发生率高，组问有统计学差异（P〈0．05），但均叮耐受。结论Topotecan联合顺铂方案是一种有效的治疗非小细胞肺癌脑转移的化疗方案。

Clinical efficacy of whole brain radiotherapy and Topotecan/ cisplatin regimen to treat non - small cell lung cancer

Objective To evaluate the clinical efficacy of Topotecan/cisplatin regimen to treat brain metastasis with non - small cell lung cancer. Methods 64 cases brain metastasis with Advanced non - small cell lung cancer, The patients were random divided into two groups. 32 previously untreated patients with brain metastasis of non - small cell lung cancer were treated by whole brain radiotherap and Topoteean/cisplatin regimen. 32 others were treated by whole brain radiotherap and gemcitabine/cisplatin regimen. Results The Topotecan/cisplatin treatment achieved a significant proportion of response rate from brain MRI/CTscan. TFFP group, the brain response rate was59.38% ,the lung response rate was62.50%, that of GP group was53.13% ,56.25%. between two groups had significant difference（P = 0. 023）. The major toxic and side effects, leukopenia and thromboeytopenia were not increased. Then there was no significant difference of response rate between group （ P 〉 0.05）. Conclusion The Topotecan/cisplatin is avalid chemotherapy regimen to treat brain metastasis patients with non - small cell lung cancer.